Personalis (NASDAQ:PSNL) Shares Down 4.8% – Should You Sell?

Personalis, Inc. (NASDAQ:PSNL)’s share price fell 4.8% during trading on Friday . The company traded as low as $8.38 and last traded at $8.4780. 194,504 shares changed hands during trading, a decline of 85% from the average session volume of 1,274,530 shares. The stock had previously closed at $8.91.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PSNL. BTIG Research upped their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Needham & Company LLC increased their price objective on Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Lake Street Capital reissued a “buy” rating and issued a $11.00 price target on shares of Personalis in a research report on Wednesday, November 5th. Morgan Stanley increased their price target on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Finally, Guggenheim upped their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.86.

Personalis Stock Down 8.8%

The company’s 50-day simple moving average is $8.79 and its 200-day simple moving average is $7.81. The stock has a market cap of $721.50 million, a price-to-earnings ratio of -9.23 and a beta of 1.98.

Insider Activity

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer directly owned 164,458 shares in the company, valued at $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 3.80% of the company’s stock.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. boosted its position in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares during the last quarter. Oracle Investment Management Inc. boosted its holdings in shares of Personalis by 47.9% in the 4th quarter. Oracle Investment Management Inc. now owns 339,343 shares of the company’s stock worth $2,701,000 after buying an additional 109,908 shares during the last quarter. First Manhattan CO. LLC. purchased a new position in shares of Personalis in the fourth quarter valued at $2,976,000. Guggenheim Capital LLC purchased a new stake in shares of Personalis during the 4th quarter valued at $108,000. Finally, AQR Capital Management LLC bought a new stake in Personalis during the fourth quarter worth about $82,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.